These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 33880083)
21. Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients. Freeman L; Kee A; Tian M; Mehta R Clinicoecon Outcomes Res; 2021; 13():65-75. PubMed ID: 33519217 [TBL] [Abstract][Full Text] [Related]
22. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. Burks J; Marshall TS; Ye X Clinicoecon Outcomes Res; 2017; 9():251-260. PubMed ID: 28496344 [TBL] [Abstract][Full Text] [Related]
23. The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis. Freedman MS; Duquette P; Grand'Maison F; Lee L; Vorobeychik G; Lara N; Khurana V; Nakhaipour HR; Schecter R; Haddad P Curr Med Res Opin; 2019 May; 35(5):767-776. PubMed ID: 30614288 [TBL] [Abstract][Full Text] [Related]
24. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis. Braune S; Lang M; Bergmann A; J Neurol; 2016 Feb; 263(2):327-333. PubMed ID: 26645389 [TBL] [Abstract][Full Text] [Related]
26. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. Vollmer B; Ontaneda D; Harris H; Nair K; Bermel RA; Corboy JR; Fox RJ; Vollmer T; Cohen JA; Alvarez E; Hersh CM J Neurol Sci; 2019 Dec; 407():116498. PubMed ID: 31644992 [TBL] [Abstract][Full Text] [Related]
27. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study. Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075 [TBL] [Abstract][Full Text] [Related]
28. Treatment Patterns, Healthcare Resource Utilization, and Costs Among Medicare Patients with Multiple Sclerosis in Relation to Disease-Modifying Therapy and Corticosteroid Treatment. Sanchirico M; Caldwell-Tarr A; Mudumby P; Hashemi L; Dufour R Neurol Ther; 2019 Jun; 8(1):121-133. PubMed ID: 30565050 [TBL] [Abstract][Full Text] [Related]
29. Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis. Earla JR; Hutton GJ; Thornton JD; Chen H; Johnson ML; Aparasu RR Explor Res Clin Soc Pharm; 2021 Jun; 2():100021. PubMed ID: 35481133 [TBL] [Abstract][Full Text] [Related]
30. Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis. Teter B; Agashivala N; Kavak K; Chouhfeh L; Hashmonay R; Weinstock-Guttman B Mult Scler; 2014 Jun; 20(7):830-6. PubMed ID: 24277325 [TBL] [Abstract][Full Text] [Related]
31. Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States. Araujo L; Kyatham S; Bzdek KG; Higuchi K; Greene N Clinicoecon Outcomes Res; 2023; 15():361-373. PubMed ID: 37234086 [TBL] [Abstract][Full Text] [Related]
32. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East. Achiron A; Aref H; Inshasi J; Harb M; Alroughani R; Bijarnia M; Cooke K; Yuksel O BMC Neurol; 2017 Aug; 17(1):150. PubMed ID: 28784108 [TBL] [Abstract][Full Text] [Related]